These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10538922)

  • 1. Assessment of biotechnology drugs: what are the issues?
    van Rijkom J; Leufkens H; Crommelin D; Rutten F; Broekmans A
    Health Policy; 1999 Jun; 47(3):255-74. PubMed ID: 10538922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotechnology: a special case for health technology assessment?
    Mason J; Drummond M
    Health Policy; 1997 Jul; 41(1):73-81. PubMed ID: 10169063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Industry-sponsored clinical research: a double-edged sword.
    Montaner JS; O'Shaughnessy MV; Schechter MT
    Lancet; 2001 Dec; 358(9296):1893-5. PubMed ID: 11741648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of biotechnology drugs: what are the issues?
    McKenna SP; Whalley D
    Health Policy; 1999 Nov; 49(3):195-7. PubMed ID: 11009833
    [No Abstract]   [Full Text] [Related]  

  • 5. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotechnology: will it break the health care bank?
    McGivney WT
    Physician Exec; 1992; 18(5):35-6. PubMed ID: 10121675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DEFINING INNOVATION WITH RESPECT TO NEW MEDICINES: A SYSTEMATIC REVIEW FROM A PAYER PERSPECTIVE.
    de Solà-Morales O; Cunningham D; Flume M; Overton PM; Shalet N; Capri S
    Int J Technol Assess Health Care; 2018 Jan; 34(3):224-240. PubMed ID: 29987996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulating biotechnology: a rational-political model of policy development.
    Wiktorowicz M; Deber R
    Health Policy; 1997 May; 40(2):115-38. PubMed ID: 10167067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Introduction to "Recent Trends in the Biotechnology Industry: Development and Manufacturing of Recombinant Antibodies and Proteins".
    Pohlscheidt M; Kiss R; Gottschalk U
    Adv Biochem Eng Biotechnol; 2018; 165():1-8. PubMed ID: 29748871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical benchmarks 2014.
    Walsh G
    Nat Biotechnol; 2014 Oct; 32(10):992-1000. PubMed ID: 25299917
    [No Abstract]   [Full Text] [Related]  

  • 12. Follow-on biologics: data exclusivity and the balance between innovation and competition.
    Grabowski H
    Nat Rev Drug Discov; 2008 Jun; 7(6):479-88. PubMed ID: 18469828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutical benchmarks.
    Walsh G
    Nat Biotechnol; 2000 Aug; 18(8):831-3. PubMed ID: 10932150
    [No Abstract]   [Full Text] [Related]  

  • 14. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How a collaborative task force can assist in managing biotechnology products.
    MacKinnon GE
    Hosp Formul; 1994 Jul; 29(7):526-30, 533. PubMed ID: 10135146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotechnology drugs create new maze of concerns for hospitals.
    Lumsdon K
    Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical benchmarks 2018.
    Walsh G
    Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report blames NICE for hastening decline of UK biotech.
    Moran N
    Nat Biotechnol; 2009 Mar; 27(3):215-7. PubMed ID: 19270658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.